公开(公告)号：US11883413B2

公开(公告)日：2024-01-30

申请号：US17358852

申请日：2021-06-25

Applicant: Institute For Cancer Research ,  Institut Curie ,  Institut de Genetique et de Biologie Moleculaire et Cellulaire

Inventor： Alfonso Bellacosa ,  Rossella Tricarico ,  Tim Yen ,  Vikram Bhattacharjee ,  Pietro Mancuso ,  Lionel Larue ,  Irwin Davidson

IPC: A61K31/5575 ,  A61K31/122 ,  A61K31/277 ,  A61K31/475 ,  A61K31/495 ,  A61K31/546 ,  A61P35/00 ,  A61K31/609 ,  A61K31/473 ,  A61K31/404 ,  A61K31/353 ,  A61K33/243 ,  A61K33/24

CPC classification number: A61K31/5575 ,  A61K31/122 ,  A61K31/277 ,  A61K31/353 ,  A61K31/404 ,  A61K31/473 ,  A61K31/475 ,  A61K31/495 ,  A61K31/546 ,  A61K31/609 ,  A61K33/24 ,  A61K33/243 ,  A61P35/00 ,  C12N2740/15043

Abstract: The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.

公开(公告)号：US20160199381A1

公开(公告)日：2016-07-14

申请号：US15084680

申请日：2016-03-30

Applicant: Institute for Cancer Research d/b/a/ The Research Institute of Fox Chase Cancer Center ,  Institut Curie ,  Institut de Génétique et de Biologie Moléculaire et Cellulaire

Inventor： Alfonso Bellacosa ,  Rossella Tricarico ,  Tim Yen ,  Vikram Bhattacharjee ,  Pietro Mancuso ,  Lionel Larue ,  Irwin Davidson

IPC: A61K31/546 ,  A61K31/277 ,  A61K31/475 ,  A61K31/122 ,  A61K31/495 ,  A61K33/24

CPC classification number: A61K31/5575 ,  A61K31/122 ,  A61K31/277 ,  A61K31/353 ,  A61K31/404 ,  A61K31/473 ,  A61K31/475 ,  A61K31/495 ,  A61K31/546 ,  A61K31/609 ,  A61K33/24 ,  C12N2740/15043

Abstract: The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.

Abstract translation: 本发明提供用于诱导表达胸腺嘧啶DNA糖基化酶的癌细胞的生长停滞，分化或衰老的组合物，试剂盒和方法，并相应地治疗癌症。 所述方法包括抑制癌细胞中胸腺嘧啶DNA糖基化酶的表达或生物学活性。 癌细胞中胸腺嘧啶DNA糖基化酶的抑制可诱导细胞恢复健康的非癌性表型和/或诱导细胞衰老。 癌细胞包括黑素瘤，肺，前列腺，胰腺，卵巢，脑，结肠，直肠乙状结肠和乳腺癌细胞。

公开(公告)号：US20240190817A1

公开(公告)日：2024-06-13

申请号：US18043548

申请日：2021-08-30

Applicant: Institute For Cancer Research D/B/A The Research Institute of Fox Chase Cancer Center

Inventor： Alfonso Bellacosa ,  John Karanicolas ,  Timothy J. Yen ,  Michael Cory ,  Chris Parry ,  Rahul Prasad

IPC: C07C311/21 ,  A61K31/18 ,  A61K31/4439 ,  C07D401/12

CPC classification number: C07C311/21 ,  A61K31/18 ,  A61K31/4439 ,  C07D401/12

Abstract: Phenylsulfonamido compounds that inhibit genome-wide hypomethylation and can be used to treat cancer, including melanoma, prostate cancer, pancreatic cancer, breast cancer, colon cancer, lung cancer, ovarian cancer, and glioblastoma, are provided.

公开(公告)号：US20220054500A1

公开(公告)日：2022-02-24

申请号：US17358852

申请日：2021-06-25

Applicant: Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center ,  Institut Curie ,  Institut de Genetique et de Biologie Moleculaire et Cellulaire

Inventor： Alfonso Bellacosa ,  Rossella Tricarico ,  Tim Yen ,  Vikram Bhattacharjee ,  Pietro Mancuso ,  Lionel Larue ,  Irwin Davidson

IPC: A61K31/5575 ,  A61K31/495 ,  A61K31/475 ,  A61K31/277 ,  A61K31/609 ,  A61K31/473 ,  A61K31/122 ,  A61K31/404 ,  A61K31/546 ,  A61K31/353 ,  A61P35/00 ,  A61K33/243 ,  A61K33/24

Abstract: The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.

公开(公告)号：US11077121B2

公开(公告)日：2021-08-03

申请号：US15084680

申请日：2016-03-30

Applicant: Institute for Cancer Research ,  Institut Curie ,  Institut de Génétique et de Biologie Moléculaire et Cellulaire

Inventor： Alfonso Bellacosa ,  Rossella Tricarico ,  Tim Yen ,  Vikram Bhattacharjee ,  Pietro Mancuso ,  Lionel Larue ,  Irwin Davidson

IPC: A61K31/5575 ,  A61K31/495 ,  A61K33/24 ,  A61K31/475 ,  A61K31/277 ,  A61K31/609 ,  A61K31/473 ,  A61K31/122 ,  A61K31/404 ,  A61K31/546 ,  A61K31/353 ,  A61P35/00

Abstract: The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.

公开(公告)号：US10220051B2

公开(公告)日：2019-03-05

申请号：US14540428

申请日：2014-11-13

Applicant: Institute for Cancer Research

Inventor： Alfonso Bellacosa ,  Timothy Yen ,  Neil Beeharry ,  Mitchell Smith ,  Rossella Tricarico ,  Vikram Bhattacharjee ,  Pietro Mancuso

IPC: A61K31/7068 ,  A61K31/4184 ,  A61K31/122 ,  A61K31/546 ,  A61K31/277 ,  A61K31/7088 ,  C12N15/113

Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.

公开(公告)号：US08927516B2

公开(公告)日：2015-01-06

申请号：US13836414

申请日：2013-03-15

Applicant: Institute for Cancer Research

Inventor： Alfonso Bellacosa ,  Timothy Yen ,  Neil Beeharry ,  Mitchell Smith

IPC: C12N15/113 ,  A61K31/4184 ,  A61K31/7068 ,  A61K31/7088

CPC classification number: C12N15/1137 ,  A61K31/4184 ,  A61K31/7068 ,  A61K31/7088 ,  C12N2310/14 ,  C12N2320/31 ,  C12Y302/02029 ,  A61K2300/00

Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.

Abstract translation: 本发明提供了增强表达胸腺嘧啶DNA糖基化酶的癌细胞中DNA损伤的细胞毒性的方法，并相应地治疗肿瘤。 所述方法包括抑制胸腺嘧啶DNA糖基化酶的表达或生物活性，并诱导癌细胞中的DNA损伤。 DNA损伤可以通过给予癌细胞给予苯达莫司汀或吉西他滨诱导。

公开(公告)号：US20130303588A1

公开(公告)日：2013-11-14

申请号：US13836414

申请日：2013-03-15

Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center

Inventor： Alfonso Bellacosa ,  Timothy Yen ,  Neil Beeharry ,  Mitchell Smith

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  A61K31/4184 ,  A61K31/7068 ,  A61K31/7088 ,  C12N2310/14 ,  C12N2320/31 ,  C12Y302/02029 ,  A61K2300/00

Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.